These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 14671426)

  • 1. Penetration of antimicrobial agents into the prostate.
    Charalabopoulos K; Karachalios G; Baltogiannis D; Charalabopoulos A; Giannakopoulos X; Sofikitis N
    Chemotherapy; 2003 Dec; 49(6):269-79. PubMed ID: 14671426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial prostatitis: new methods of treatment.
    Aagaard J; Madsen PO
    Urology; 1991; 37(3 Suppl):4-8. PubMed ID: 2003343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial treatment of prostatitis.
    Wagenlehner FM; Naber KG
    Expert Rev Anti Infect Ther; 2003 Aug; 1(2):275-82. PubMed ID: 15482123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts in antimicrobial therapy of prostatitis.
    Ristuccia AM; Cunha BA
    Urology; 1982 Sep; 20(3):338-45. PubMed ID: 6981874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antibiotics in chronic bacterial prostatitis.
    Wagenlehner FM; Weidner W; Sörgel F; Naber KG
    Int J Antimicrob Agents; 2005 Jul; 26(1):1-7. PubMed ID: 15970433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis.
    Itoh M; Katoh N; Ono Y; Ohshima S; Miyake K
    Urol Int; 1995; 55(2):101-4. PubMed ID: 8533190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.
    Nishikawa G; Ikawa K; Nakamura K; Yamada Y; Zennami K; Mitsui K; Narushima M; Ikeda K; Morikawa N; Sumitomo M
    Int J Antimicrob Agents; 2013 Mar; 41(3):267-71. PubMed ID: 23313536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?
    Gardiner BJ; Mahony AA; Ellis AG; Lawrentschuk N; Bolton DM; Zeglinski PT; Frauman AG; Grayson ML
    Clin Infect Dis; 2014 Feb; 58(4):e101-5. PubMed ID: 24170195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of antibiotics in chronic prostatitis syndromes.
    Shoskes DA
    Can J Urol; 2001 Jun; 8 Suppl 1():24-8. PubMed ID: 11442994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate.
    Goto T; Makinose S; Ohi Y; Yamauchi D; Kayajima T; Nagayama K; Hayami H
    Int J Urol; 1998 May; 5(3):243-6. PubMed ID: 9624555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid.
    Stamey TA; Meares EM; Winningham DG
    Trans Am Assoc Genitourin Surg; 1969; 61():27-34. PubMed ID: 4900657
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of lomefloxacin in the treatment of chronic prostatitis.
    Scelzi S; Travaglini F; Nerozzi S; Dominici A; Ponchietti R; Novelli A; Rizzo M
    J Chemother; 2001 Feb; 13(1):82-7. PubMed ID: 11233805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, pharmacologic considerations, and management of prostatitis.
    Schiller DS; Parikh A
    Am J Geriatr Pharmacother; 2011 Feb; 9(1):37-48. PubMed ID: 21459307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and therapeutic problems in prostatitis. Therapeutic position of ofloxacin.
    Aagaard J; Madsen PO
    Drugs Aging; 1992; 2(3):196-207. PubMed ID: 1606353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial substances in secretion, interstitial fluid, and tissue of normal and infected canine prostate glands.
    Baumueller A; Madsen PO
    Urol Res; 1982 Feb; 10(1):31-5. PubMed ID: 7200274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and chronic bacterial prostatitis: a review of treatment approaches.
    Kot T; Pettit-Young N
    Compr Ther; 1990 Aug; 16(8):54-9. PubMed ID: 2173653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
    Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
    J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.
    Wagenlehner FM; Kees F; Weidner W; Wagenlehner C; Naber KG
    Int J Antimicrob Agents; 2008 Jan; 31(1):21-6. PubMed ID: 18054465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis.
    Dorfman M; Barsanti J; Budsberg SC
    Am J Vet Res; 1995 Mar; 56(3):386-90. PubMed ID: 7771709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic therapy--rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue.
    Naber KG; Sörgel F
    Andrologia; 2003 Oct; 35(5):331-5. PubMed ID: 14535866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.